Antibiotic Dosing for Uncomplicated Adult Skin Abscess After Incision-and-Drainage
For uncomplicated adult skin abscesses after incision-and-drainage, prescribe trimethoprim-sulfamethoxazole 1-2 double-strength tablets (160/800 mg) twice daily for 7 days.
Rationale and Evidence
The 2014 IDSA guidelines 1 provide the foundational framework, recommending antibiotics active against MRSA for patients with carbuncles or abscesses who have failed initial treatment, have markedly impaired host defenses, or present with SIRS and hypotension. However, the landmark 2016 NEJM trial 2 demonstrated that trimethoprim-sulfamethoxazole significantly improves outcomes even in uncomplicated cases, with clinical cure rates of 92.9% versus 85.7% with placebo (P<0.001) in settings where MRSA prevalence is high.
Specific Dosing Recommendations
From the IDSA guidelines 1, the standard adult dosing options for MRSA-active antibiotics include:
- Trimethoprim-sulfamethoxazole: 1-2 double-strength tablets twice daily (preferred based on trial evidence)
- Doxycycline or minocycline: 100 mg twice daily (alternative)
- Clindamycin: 300-450 mg four times daily (alternative, but concern for inducible resistance)
Duration of Therapy
The evidence supports 7 days of treatment 2. This duration achieved:
- Lower rates of subsequent surgical drainage (3.4% vs 8.6%)
- Reduced skin infections at new sites (3.1% vs 10.3%)
- Fewer household member infections (1.7% vs 4.1%)
When to Prescribe Antibiotics
While the IDSA guidelines 1 traditionally reserved antibiotics for complicated cases, contemporary evidence 2, 3 now supports routine antibiotic use after drainage in settings with MRSA prevalence, particularly when:
- MRSA is prevalent in your community (>30% of S. aureus isolates)
- The abscess required surgical drainage
- You want to prevent recurrence and new lesions
Clinical Indicators for Mandatory Antibiotics
Per IDSA guidelines 1, antibiotics are strongly recommended when:
- SIRS criteria present: Temperature >38°C or <36°C, tachypnea >24 breaths/min, tachycardia >90 bpm, or WBC >12,000 or <4,000 cells/μL
- Failed initial treatment
- Markedly impaired host defenses (immunosuppression, diabetes, liver/kidney failure)
- Hypotension or systemic toxicity
Important Caveats
Gastrointestinal side effects: Trimethoprim-sulfamethoxazole causes slightly more GI symptoms than placebo, though mostly mild 2. Counsel patients accordingly.
Invasive infection risk remains low: Only 0.4% developed invasive infections in both treatment and placebo groups 2, so antibiotics primarily prevent local recurrence rather than systemic complications.
Avoid routine packing: Recent evidence 3 clearly shows packing offers no outcome advantage and increases pain—use simple dressings instead.